The FDA has approved Jascayd (nerandomilast) as a treatment for a second lung disease, progressive pulmonary fibrosis, following the drug’s initial approval in October 2025 as a treatment for ...
Savara Inc. (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced today that it has resubmitted the MOLBREEVI BLA to the FDA, with Fujifilm as the ...
Having low lung function as a middle-aged smoker without airway obstruction raised the likelihood for all-cause mortality, ...
Winter smog is not merely an environmental nuisance, it poses a serious health threat to people living with Interstitial Lung Diseases ...
Lung development begins during embryogenesis and continues after birth. It includes branching of airways, formation of ...
Poor air quality impacts the health of children severely. Fine particulate matter like PM2.5, coarse particles such as PM10, ...
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, ...
Shilpa Medicare Serves as Lead Investor, Positioning Alveolus Bio for Phase 2 Clinical Trials and First-in-Human Studies "Securing Shilpa as our lead investor is a transformative step," said Gaurav ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback